Literature DB >> 646245

Serial plasma carcinoembryonic antigen measurements in the management of metastatic colorectal carcinoma.

A Shani, M J O'Connell, C G Moertel, A J Schutt, A Silvers, V L Go.   

Abstract

Serial carcinoembryonic antigen (CEA) measurements were evaluated in a group of 263 patients undergoing systemic chemotherapy for metastatic colorectal carcinoma. Initial CEA levels were not found to be of value in predicting the likelihood of subsequent tumor response. Although a general relation between serial CEA measurements and clinical tumor measurements was noted, these measurements were discordant in a substantial proportion of patients. Tumor measurements as an index of response to therapy were strongly correlated with survival, whereas changes in CEA values and patient survival were not correlated at a statistically significant level. Serial CEA measurements were perhaps of some value in predicting progression of malignant disease, and were roughly comparable to serum alkaline phosphatase assay in assessing response of liver metastasis to chemotherapy. Overall, serial CEA measurements added little to the standard clinical assessment of patients with advanced colorectal carcinoma receiving chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 646245     DOI: 10.7326/0003-4819-88-5-627

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  10 in total

1.  Carcinoembryonic antigen reduction after medical treatment in patients with metastatic colorectal cancer: a systematic review and meta-analysis.

Authors:  Giuseppe Antonio Colloca; Antonella Venturino; Domenico Guarneri
Journal:  Int J Colorectal Dis       Date:  2019-01-22       Impact factor: 2.571

2.  Specificity of tumor markers (CEA, GICA, TPA, alpha-FP, FpA, gamma-GT) for the diagnosis of hepatic metastases from large bowel cancers.

Authors:  V Abbasciano; F Levato; G Zavagli
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

Review 3.  The role of carcinoembryonic antigen monitoring in management of colorectal cancer.

Authors:  M F Mulcahy; A B Benson
Journal:  Curr Oncol Rep       Date:  1999       Impact factor: 5.075

4.  Carcinoembryonic antigen: physician attitudes, patterns of use, and impact upon patient care.

Authors:  S L Vest; J K Roche
Journal:  Dig Dis Sci       Date:  1982-04       Impact factor: 3.199

5.  MItomycin C, methyl-CCNU and 5-fluorouracil in the treatment of metastatic colorectal carcinoma.

Authors:  P D Bonomi; G Chandra; A H Rossof; D Klaassen
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

6.  Comparative analysis of cancer-associated antigen CA-195, CA 19-9 and carcinoembryonic antigen in diagnosis, follow-up and monitoring of response to chemotherapy in patients with gastrointestinal cancer.

Authors:  G Kornek; D Depisch; E M Temsch; W Scheithauer
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 7.  The detection and evaluation of human tumor metastases.

Authors:  D J Laurence; A M Neville
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

8.  Vindesine: phase II evaluation in colon cancer and description of its platelet stimulating activity.

Authors:  R Pazdur; A H Rossof; G Chandra; P D Bonomi; R E Slayton; J Wolter
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  Tumour lysis as a factor affecting blood levels of CEA.

Authors:  J B Quayle
Journal:  Br J Cancer       Date:  1982-08       Impact factor: 7.640

10.  Evaluation of CEA in patients with known residual disease after resection of colonic cancer.

Authors:  J O Lawton; G R Giles; E H Cooper
Journal:  J R Soc Med       Date:  1980-01       Impact factor: 18.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.